Organisation paid for research Program year 2025 Source: CMS Open Payments

Vivida Dermatology

Neither a doctor nor a teaching hospital

Research payments

$80,030

6 payments

Through program year 2025, Vivida Dermatology is reported as receiving $80,030 in research payments, across 6 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$7,161	1
2022	Research	$65,398	1
2020	Research	$7,471	4

Breakdown

Who paid Research payments · program years 2020–2025

Amgen Inc. $65,398 1 payment
Pfizer Inc. $7,471 4 payments
Novartis Pharmaceuticals Corporation $7,161 1 payment

Studies the money was for Research payments · program years 2020–2025

P3 switching study PK; plaque psoriasis $65,398 1 payment
A Phase 3B Randomized Doubleblind Doubledummy Active Controlled Multicenter Study Assessing the Efficacy and Safety of Abrocitinib Compared With Dupilumab in Adult Participants on Background Topical Therapy With Moderate to Severe Atopic Dermatitis $7,471 4 payments
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup $7,161 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.